obesity drug news today glp-1 Retatrutide for weight loss: Study shows 30% body weight loss Pharma Giants Bet on Next-Generation

(2023) 46:S128S39

Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial)

Inflammation in Parkinsons Disease: Mechanisms and Therapeutic Implications

The functions of TRPA1 and TRPV1: moving away from sensory neurons

HF severity is characterized by the increase in inflammation [108], where the use of SGLT2is increases the circulating levels of -hydroxybutyrate, which is an effective blocker of the NLRP3 inflammasome-mediated inflammatory process, which plays an important role in mediating inflammation [110,111]

analysis [37], patients on GLP-1 RAs (exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, tirzepatide) had a significantly lower 1-year shunt placement rate (OR 0.375, 95% CI 0.1710.753, p = 0.047)